appears in the following:

HHS To Help Companies Develop COVID-19 Vaccines

Tuesday, March 31, 2020

The Department of Health and Human Services outlines support for Moderna and Johnson & Johnson, as the companies work to develop coronavirus vaccines. Beefing up manufacturing capacity is a priority.

Comment

FDA OKs Addition To Stockpile Of Malaria Drugs For COVID-19

Monday, March 30, 2020

Chloroquine and hydroxycloroquine got the Food and Drug Administration's go-ahead to be put in the nation's strategic storehouses. But the drugs haven't been approved to treat coronavirus patients.

Comment

Gilead Declines 'Rare Disease' Status For Experimental Coronavirus Drug

Wednesday, March 25, 2020

By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and seven years without generic competition for remdesivir, its experimental COVID-19 treatment.

Comment

FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease Treatments

Tuesday, March 24, 2020

Gilead Science's remdesivir, an antiviral medicine being tested for treatment of COVID-19, would get a seven-year monopoly if approved by the Food and Drug Administration.

Comment

Might The Experimental Drug Remdesivir Work Against COVID-19?

Saturday, March 21, 2020

It's too soon to know if the antiviral compound tested in 2014 as a potential Ebola treatment will hobble the coronavirus. Lab tests show promise, but studies in people with COVID-19 have only begun.

Comment

Doctors Experiment With Existing Medicines To Find COVID-19 Cure

Friday, March 20, 2020

A vaccine against coronavirus looks to be at least a year away. Doctors are trying existing medicines that might be useful in the meantime. One appears promising.

Comment

Mask Shortage Straps Pharmacists Who Need Them To Keep Medicines Pure

Friday, March 20, 2020

Fifteen percent of hospital pharmacists who prepare injectable drugs are going without the protective masks they typically rely on, or are using substitutes for the masks.

Comment

Insurers Cover Fewer Drugs, Leaving Some Patients Struggling To Get Needed Treatments

Monday, March 16, 2020

A new report finds insurers are becoming more selective about which medications they'll cover. Patients and doctors have to work harder to get treatments approved.

Comment

Insurers Are Covering Far Fewer Drugs Than They Once Were

Monday, March 16, 2020

New research indicates that insurers are covering far fewer drugs than they did a decade ago. The reduction in options can interrupt care and leave people with hard choices at the pharmacy counter.

Comment

How Coronavirus Is Affecting The U.S. Pharmaceutical Supply

Thursday, March 12, 2020

In China, drug manufacturers are getting back to work. But supply chain disruptions could still lead to drug shortages down the road.

Comment

Hormone Blocker Sticker Shock: Kids Drug Costs 8 Times More Than One For Adults

Monday, February 24, 2020

Two nearly identical drug implants have very different prices. The one for kids has a list price of $37,300. For adults, it's $4,400. A dad fought for his daughter to be able to get the cheaper drug.

Comment

Patients Still Struggle To Balance High Costs Of MS Treatment, Despite Generic

Monday, January 20, 2020

Drugs to treat multiple sclerosis can run $70,000 a year or more. Patients hoped competition from a generic version of one of the most popular brands would spur relief, but prices went up. Here's why.

Comment

FDA Approves Drugs Faster Than Ever But Relies On Weaker Evidence, Researchers Find

Tuesday, January 14, 2020

Changes in the way the Food and Drug Administration reviews new medicines means that there are more cures and treatments on the market. But there's also less proof the drugs are safe and effective.

Comment

Trump Administration Cracks Down On Some Flavored Vaping Products

Thursday, January 02, 2020

The federal government is taking action to pull many flavored products popular with kids off the market. Public health advocates say the move doesn't go far enough.

Comment

A Decade Marked By Outrage Over Drug Prices

Tuesday, December 31, 2019

Nearly 1 in 4 Americans has trouble affording prescription drugs, according to a Kaiser Family Foundation poll. Over the past decade, high prices of several medicines have become flashpoints.

Comment

FDA Faulted For Lapses In Orphan Drug Program

Friday, November 30, 2018

The Government Accountability Office found breakdowns in the way the Food and Drug Administration evaluates drugs for rare diseases. The analysis came after an investigation by Kaiser Health News.

Comment

One-Third Of New Drugs Had Safety Problems After FDA Approval

Tuesday, May 09, 2017

More than 70 drugs approved by the FDA from 2001 to 2010 ran into safety concerns that prompted withdrawals from the market, "black box" warnings or other actions.

Comment

GOP Senators Ask GAO To Investigate High Prices For Orphan Drugs

Tuesday, March 07, 2017

Amid an uproar over soaring drug prices, three GOP senators are seeking an investigation into whether the Orphan Drug Act is being manipulated to jack up the cost of medications for rare diseases.

Comment

Duchenne Drug Delayed After Outrage Over Price

Tuesday, February 14, 2017

Many Duchenne muscular dystrophy patients in the U.S. have imported a medicine called deflazacort for about $1,200 a year. A brand-name version just approved for sale in America costs $89,000.

Comment

6 Senators Assessing Trump's HHS Nominee Own Health Care Stocks, Too

Wednesday, January 18, 2017

A half-dozen senators involved in confirmation hearings for Rep. Tom Price to head the Department of Health and Human Services have health care investments made by themselves or family members.

Comment